Exploring vortioxetine combination with intranasal esketamine: A feasible alternative to SSRI/SNRI? - Insights from the REAL-ESK study
Journal of Affective Disorders · 2024-12 · 367 · 583-588
DOI: 10.1016/j.jad.2024.09.004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Affective Disorders, 2024-12. Verfasst von Giacomo d'Andrea und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosciences, Imaging and Clinical Sciences, Università degli Studi G. D'Annunzio, Chieti, Italy.; Department of Mental Health, ASL 02…. Hauptthemen laut MEDLINE: Vortioxetine, Administration, Intranasal, Drug Therapy, Combination, Ketamine. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Treatment-Resistant Depression (TRD) affects almost 30 % of patients with Major Depressive Disorder (MDD). Esketamine Nasal Spray (ESK-NS) has recently been approved for TRD in combination with a Serotonin Specific Reuptake Inhibitor/SSRI or a Serotonin-Norepinephrine Reuptake Inhibitor/SNRI. There is a lack of studies investigating the effectiveness and safety of ESK-NS in combination with other oral antidepressants. AIM: To assess the efficacy of Vortioxetine plus ESK-NS in mitigating depressive symptoms and emotional blunting, as well as its tolerability in TRD subjects, compared to the standard-of-care of SSRI/SNRI plus ESK-NS. METHODS: We conducted a post-hoc analysis of the REAL-ESK study. The study included twenty TRD patients, ten subjects taking Vortioxetine as the main oral antidepressant with ESK-NS, and ten subjects taking SSRI or SNRI with ESK-NS. Psychometric assessments (Montgomery-Åsberg Depression Rating Scale/MADRS, Brief Psychiatric Rating Scale/BPRS) were conducted at baseline(T0), one month(T1), and three months after the treatment initiation(T2). RESULTS: The combination of Vortioxetine and ESK-NS was as effective as the standard-of-care in reducing depressive symptoms, with a higher effect size in reducing emotional blunting at T2. The safety and tolerability profile of the Vortioxetine+ESK-NS combination appeared to be better, with a lower rate of treatment-emergent adverse events. CONCLUSION: The combination of Vortioxetine and ESK-NS may be a valuable alternative to the standard-of-care SSRI/SNRI plus ESK-NS in TRD patients, particularly regarding the reduction of emotional blunting and potentially a better safety and tolerability profile. Further randomized controlled trials with larger sample sizes and prospective designs are needed to confirm these findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosciences, Imaging and Clinical Sciences, Università degli Studi G. D'Annunzio, Chieti, Italy.; Department of Mental Health, ASL 02 Lanciano-Vasto-Chieti, Chieti, Italy.
- Department of Mental Health, ASL 02 Lanciano-Vasto-Chieti, Chieti, Italy.. Electronic address: andreamiuli@live.it.
- Department of Neurosciences, Imaging and Clinical Sciences, Università degli Studi G. D'Annunzio, Chieti, Italy.
- Department of Mental Health, ASL 02 Lanciano-Vasto-Chieti, Chieti, Italy.
- Department of Neuropsychiatry, Villa Von Siebenthal Neuropsychiatric Clinic, Genzano di Roma, Italy.
- ASL Napoli 1 Centro, Department of Mental Health, Napoli, Italy.
Zitieren
APA
d'Andrea, G., Miuli, A., Pettorruso, M., Cavallotto, C., Marrangone, C., Cocco, A., De Filippis, S., Martiadis, V., Andriola, I., Barlati, S., Vita, A., Dell'Osso, B. M., Sensi, S. L., Di Lorenzo, G., & Martinotti, G. (2024). Exploring vortioxetine combination with intranasal esketamine: A feasible alternative to SSRI/SNRI? - Insights from the REAL-ESK study. Journal of Affective Disorders, 367, 583-588. https://doi.org/10.1016/j.jad.2024.09.004
Vancouver
d'Andrea G, Miuli A, Pettorruso M, Cavallotto C, Marrangone C, Cocco A, et al. Exploring vortioxetine combination with intranasal esketamine: A feasible alternative to SSRI/SNRI? - Insights from the REAL-ESK study. Journal of Affective Disorders. 2024;367:583-588. doi:10.1016/j.jad.2024.09.004
BibTeX
@article{dAndrea2024,
author = {d'Andrea, Giacomo and Miuli, Andrea and Pettorruso, Mauro and Cavallotto, Clara and Marrangone, Carlotta and Cocco, Alessio and De Filippis, Sergio and Martiadis, Vassillis and Andriola, Ileana and Barlati, Stefano and Vita, Antonio and Dell'Osso, Bernardo Maria and Sensi, Stefano L and Di Lorenzo, Giorgio and Martinotti, Giovanni},
title = {Exploring vortioxetine combination with intranasal esketamine: A feasible alternative to SSRI/SNRI? - Insights from the REAL-ESK study},
journal = {Journal of Affective Disorders},
year = {2024},
volume = {367},
pages = {583--588},
doi = {10.1016/j.jad.2024.09.004}
}
EUVIMED